NCT00637832 2022-01-06
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
Phase 2 Terminated
Clinical Trials
12 trialsNCT01434472 2021-07-20
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00582166 2019-12-13
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
University of Wisconsin, Madison
Phase 2 Terminated
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00110149 2017-11-21
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Terminated
NCT01207765 2017-03-20
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Tufts Medical Center
Phase 2 Terminated
NCT01497275 2015-07-15
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Duke University
Phase 2 Terminated
NCT00033423 2013-12-13
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Alabama at Birmingham
Phase 1 Terminated
NCT00493454 2013-05-31
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00060294 2013-01-08
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT00902525 2012-12-31
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase 2 Terminated
NCT00354822 2009-09-18
Z0105
A.O. Ospedale Papa Giovanni XXIII
Phase 2 Terminated